Standard Modifiable Cardiovascular Risk Factors and Prognostic Outcomes in Non-Valvular Atrial Fibrillation Patients on Oral Anticoagulants
Clinical and Applied Thrombosis/Hemostasis · 2026
DOI: 10.1177/10760296261442055 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Applied Thrombosis/Hemostasis, 2026. Verfasst von Linhao Liu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Tianjin Medical University General Hospital, Tianjin Medical University, Tianjin, China. Hauptthemen laut MEDLINE: Atrial Fibrillation, Anticoagulants, Cardiovascular Diseases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China, Tianjin Key Medical Discipline (Specialty) Construction Project.
Abstract (Originalsprache)
Background
Standard Modifiable Cardiovascular Risk Factors (SMurfs) influence Atrial fibrillation (AF). However, data on their cumulative prognostic effect in Asian non-valvular AF (NVAF) patients receiving oral anticoagulants (OACs) remain limited. This study investigated the association between the cumulative burden of SMurfs and the prognosis of these NVAF patients on oral anticoagulation (OAC) therapy.
Methods
This retrospective cohort study used Tianjin Health and Medical Data Platform (THMDP) data on 20 782 NVAF patients on OACs between 2015 and 2020. Patients were categorized into groups by the number of baseline SMurfs (0, 1-2, or 3-4: hypertension, diabetes, hyperlipidemia, smoking). Cox proportional hazards models assessed the association between SMurf burden group and the primary outcome (all-cause mortality) and secondary outcomes. Subgroup and sensitivity analyses were performed to evaluate the consistency and robustness of the findings.
Results
After adjusting for confounders, compared to the SMurf-less group, the hazard ratios (HRs) for all-cause mortality were 1.20 (95% confidence interval [CI]: 1.01-1.44) for the SMurf (1-2) group and 1.67 (95% CI: 1.33-2.08) for the SMurf (3-4) group. For ischemic stroke, the hazard ratio (HR) was 1.44 (95% CI: 1.03-1.99) for the SMurf (3-4) group, while the association was not significant for the SMurf (1-2) group. A more pronounced association between SMurfs and all-cause mortality was observed in patients with an estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m 2 .
Conclusion
In Asian NVAF patients receiving OACs, a higher SMurf burden is significantly associated with an increased risk of all-cause mortality and ischemic stroke.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Tianjin Medical University General Hospital, Tianjin Medical University, Tianjin, China.
- Department of Cardiology, Qingzhou People's Hospital, Weifang, China.
- Faculty of Medicine, Qilu Institute of Technology, Jinan, China.
ORCID-Profile: Linhao Liu, Hangkuan Liu, Geru Aa, Xin Zhou
Förderung
- National Natural Science Foundation of China
- National Key Research and Development Program of China
- Tianjin Key Medical Discipline (Specialty) Construction Project
Zitieren
APA
Liu, L., Liu, H., Sun, P., Aa, G., Liu, Y., Zhang, Z., Yang, Q., & Zhou, X. (2026). Standard Modifiable Cardiovascular Risk Factors and Prognostic Outcomes in Non-Valvular Atrial Fibrillation Patients on Oral Anticoagulants. Clinical and Applied Thrombosis/Hemostasis. https://doi.org/10.1177/10760296261442055
Vancouver
Liu L, Liu H, Sun P, Aa G, Liu Y, Zhang Z, et al. Standard Modifiable Cardiovascular Risk Factors and Prognostic Outcomes in Non-Valvular Atrial Fibrillation Patients on Oral Anticoagulants. Clinical and Applied Thrombosis/Hemostasis. 2026. doi:10.1177/10760296261442055
BibTeX
@article{Liu2026,
author = {Liu, Linhao and Liu, Hangkuan and Sun, Pengfei and Aa, Geru and Liu, Yuanyuan and Zhang, Zhiqiang and Yang, Qing and Zhou, Xin},
title = {Standard Modifiable Cardiovascular Risk Factors and Prognostic Outcomes in Non-Valvular Atrial Fibrillation Patients on Oral Anticoagulants},
journal = {Clinical and Applied Thrombosis/Hemostasis},
year = {2026},
doi = {10.1177/10760296261442055}
}
EUVIMED